← Back to Search

Procedure

RIC for Multiple Sclerosis

N/A

Waitlist Available

Research Sponsored by University of Calgary

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

With Primary Progressive Multiple Sclerosis, according to current diagnostic criteria

Screening timed 25-foot walk (average of two trials) of 5.5 seconds or more

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 12 months

Awards & highlights

Study Summary

This trial will test if a non-pharmaceutical, safe, and tolerable intervention (RIC) can prevent worsening of walking ability in people with primary progressive MS.

Who is the study for?

This trial is for individuals with primary progressive multiple sclerosis (PPMS). Specific eligibility criteria are not provided, but typically participants must meet certain health conditions and cannot have factors that would exclude them from safely participating in the study.Check my eligibility

What is being tested?

The trial is testing Remote Ischemic Conditioning (RIC), a non-drug treatment involving repeated cycles of transient limb ischemia. The goal is to see if it can prevent worsening walking ability in PPMS patients by promoting remyelination in the nervous system.See study design

What are the potential side effects?

While specific side effects are not listed, RIC has been considered safe and tolerable in previous stroke trials. Potential side effects may be related to temporary restriction of blood flow during treatment.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

My condition is diagnosed as Primary Progressive Multiple Sclerosis.

Select...

It takes me more than 5.5 seconds to walk 25 feet.

Select...

I am between 18 and 65 years old.

Select...

My disability score is between 4.0 and 6.5.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 12 months

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~12 months

This trial's timeline: 3 weeks for screening, Varies for treatment, and 12 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Timed 25-foot walk

Secondary outcome measures

MRI measure of remyelination

Nine Hole Peg Test

SDMT (Single digit modalities test)

Trial Design

1Treatment groups

Experimental Treatment

Group I: RICExperimental Treatment1 Intervention

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Remote ischemic conditioning

2017

Completed Phase 2

~7250

0 / 4Eligibility criteria met

Find a Location

Who is running the clinical trial?

University of CalgaryLead Sponsor

792 Previous Clinical Trials

869,109 Total Patients Enrolled

9 Trials studying Multiple Sclerosis

371 Patients Enrolled for Multiple Sclerosis

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Does this research involve participants aged 60 or younger?

"The age requirement for this trial is between 18 and 65, as stated in the study's inclusion criteria."

Answered by AI

Are there any vacant slots available for participation in this experiment?

"This investigation is no longer accepting patients; as indicated on clinicaltrials.gov, the study was posted February 28th 2024 and last updated December 6th 2023. Despite this research not being open for recruitment, 541 other trials are presently enlisting volunteers."

Answered by AI

How can I gain entrance to this clinical investigation?

"In order to be considered for this clinical trial, prospective participants are required to possess a diagnosis of multiple sclerosis and must fall within the 18-65 year age range. The study is actively seeking 45 patients in total."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Remote Ischemic Conditioning in PPMS

2024. "Remote Ischemic Conditioning in PPMS". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT06171334.